A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by International AIDS Vaccine Initiative
Sponsor:
Collaborators:
Children's Hospital of Philadelphia (CHOP)
Information provided by (Responsible Party):
International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier:
NCT01937455
First received: September 4, 2013
Last updated: January 30, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of rAAV1-PG9DP when administered intramuscularly at different dose levels in healthy male adults.


Condition Intervention Phase
HIV Infections
Biological: rAAV1-PG9DP
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

Resource links provided by NLM:


Further study details as provided by International AIDS Vaccine Initiative:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    1. Proportion of volunteers with moderate or greater reactogenicity (i.e., solicited adverse events) during a 7 day follow-up period after the injection
    2. Proportion of volunteers with moderate or greater adverse events (i.e. unsolicited adverse events) including safety laboratory (biochemical, haematological) parameters, from the day of the injection up to 180 days post injection
    3. Proportion of volunteers with serious adverse events (SAEs) related to the IMP throughout the study period
    4. The proportion of volunteers in each group with Adverse Event of Special Interest, defined as adverse events potentially caused by antigen-antibody complexes or immune responses directed to cells producing the transgene


Secondary Outcome Measures:
  • Pharmacokinetics and Immunogenicity [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To assess (qualitative and quantitative) immune responses elicited by the different dose levels.


Estimated Enrollment: 24
Study Start Date: January 2014
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
rAAV1-PG9DP or placebo (v:p = 3:1)
Biological: rAAV1-PG9DP
4x10^12 vg administered intramuscularly
Experimental: Group B
rAAV1-PG9DP or placebo (v:p = 3:1)
Biological: rAAV1-PG9DP
4x10^13 vg administered intramuscularly
Experimental: Group C/C1
rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
Biological: rAAV1-PG9DP
8x10^13 vg administered intramuscularly
Experimental: Group D/D1
rAAV1-PG9DP or placebo (v:p = 3:1 in Group D and D1)
Biological: rAAV1-PG9DP
1.2x10^14 vg administered intramuscularly

Detailed Description:

This study is a phase 1, randomized, blinded, dose-escalation study to evaluate the safety and tolerability of rAAV1-PG9DP when administered intramuscularly at 4x10^12 vg, 4x10^13 vg, 8x10^13 vg and 1.2x10^14 vg in healthy male adults.

Volunteers will be screened up to 42 days before injection and will be followed for 12 months after the single administration. It is anticipated that it will take approximately 13 months to enroll the study.

Volunteers will be randomly assigned investigational product (IP) or placebo within each of the dose groups described in the study design table above depending on which group is enrolling. Study staff and volunteers will be blinded only with respect to the allocation of placebo or IP. Blinding will not apply to the assignment of dosage levels.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male.
  2. 18 to 45 years of age.
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  4. In the opinion of the Principal Investigator or designee and based on Assessment of Informed Consent Understanding results, has understood the information provided and has provided informed consent.
  5. Willing to undergo HIV testing, risk reduction counseling and receive HIV test results.
  6. All sexually active males must be willing to use male condoms with all sexual partners (female or male) from the day of first injection until 3 months after the injection.
  7. Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV-positive due to vaccine-induced antibodies, until the anti-HIV antibody titers become undetectable.

Exclusion Criteria:

  1. Confirmed HIV-1 or HIV-2 infection.
  2. Any clinically relevant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the investigator within the previous 6 months.
  3. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator makes the volunteer unsuitable for participation in the study.
  4. Any of the following specific risk behaviour for HIV infection within 6 months prior to injection:

    • Unprotected sexual intercourse with a known HIV infected person or a partner known to be at high risk for HIV infection or a casual partner (i.e., no continuing established relationship)
    • Unprotected anal intercourse with another man (either insertive or receptive)
    • Three or more sexual partners
    • Engaged in sex work
    • Frequent excessive daily alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of illicit drugs
    • History of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, HSV-2, chlamydia, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B
  5. Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions).
  6. Clinically significant laboratory abnormalities.
  7. Anti-AAV1 antibody level above the cut-off.
  8. Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after injection with IP; or receipt of other vaccine within the previous 14 days or planned receipt within 14 days after injection with IP (exception is live attenuated influenza vaccine within 14 days).
  9. Receipt of blood transfusion or blood-derived products within the previous 3 months.
  10. Participation in another clinical trial of an IMP currently, within the previous 3 months or expected participation during this study.
  11. Prior receipt of another AAV vector, investigational HIV vaccine candidate, monoclonal antibody or polyclonal immunoglobulin (note: receipt of placebo in a previous HIV vaccine or monoclonal antibody trial will not exclude a volunteer from participation).
  12. History of severe local or systemic reactogenicity to vaccines or infusions (e.g., anaphylaxis, respiratory difficulties, angioedema)
  13. Psychiatric condition that compromises safety of the volunteer and precludes compliance with the protocol.
  14. In the opinion of the Principal Investigator, it is not in the best interest of the volunteer to participate in the trial.
  15. Seizure disorder: a participant who has had a seizure in the last 3 years.
  16. ECG with clinically significant findings or features.
  17. History of, or known active cardiovascular disease.
  18. Have 3 or more of the following risk factors:

    • Hypertension diagnosed by a doctor
    • Hypercholesterolemia diagnosed by a doctor
    • Diabetes mellitus
    • Hyperglycemia diagnosed by a doctor
    • First degree relative (i.e., mother, father, brother, sister) who had a heart condition before the age of 50
    • Currently smoke cigarettes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01937455

Locations
United Kingdom
Surrey Clinical Research Centre Recruiting
Guildford, United Kingdom, GU2 7XP
Contact: David JM Lewis, MD    +44 1483689797    D.J.Lewis@surrey.ac.uk   
Principal Investigator: David JM Lewis, MD         
Sponsors and Collaborators
International AIDS Vaccine Initiative
Children's Hospital of Philadelphia (CHOP)
Investigators
Principal Investigator: David JM Lewis, MD Clinical Research Centre, Institute of Biosciences and Medicine, FHMS, University of Surrey
  More Information

Additional Information:
No publications provided

Responsible Party: International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier: NCT01937455     History of Changes
Other Study ID Numbers: IAVI A003/CHOP HVDDT 001, 2013-002268-14, HHSN272201000021C
Study First Received: September 4, 2013
Last Updated: January 30, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee

Keywords provided by International AIDS Vaccine Initiative:
HIV
AIDS
HIV vaccine
HIV prevention
AAV
PG9

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on August 28, 2014